N@N

Somaxon Pharmaceuticals to Report Third Quarter 2010 Results and Conduct Conference Call on Tuesday, November 9

_{//health-fitness.news-articles.net/content/2010/ .. nduct-conference-call-on-tuesday-november-9.html}
^{Published in Health and Fitness on Wednesday, October 27th 2010 at 13:16 GMT by Market Wire}  

SAN DIEGO--([ BUSINESS WIRE ])--Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that it will release its third quarter 2010 financial results on Tuesday, November 9, 2010 after the closing of the U.S. financial markets. The Company will also conduct a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and highlights of the third quarter 2010.

The conference call will be available to interested parties through a live audio Internet broadcast at [ http://investors.somaxon.com/eventdetail.cfm ]. The call will also be archived and accessible at this site for approximately two weeks. Alternatively, callers may participate in the conference call by dialing (877) 941-2333 (domestic) or (480) 629-9723 (international), conference call ID 4376422. A telephonic replay will be available for approximately two weeks following the conclusion of the call by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international), and entering passcode 4376422.

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and of late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxona™s product Silenor® (doxepin), now available by prescription in the United States, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

For more information, please visit the companya™s web site at [ www.somaxon.com ].